Fust Matthew K 4

What Happened

• Matthew K. Fust, a director of Atara Biotherapeutics (ATRA), was granted 12,000 restricted stock units (RSUs) on 2026-06-09. The Form 4 lists the acquisition price as $0.00 (award), so no cash was paid at grant.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-11 (appears to be within the typical 2-business-day reporting window).
• Transaction type: Award/Grant (code A) — 12,000 RSUs, acquisition price $0.00.
• Shares owned after transaction: not specified in the filing.
• Vesting note: These RSUs vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to Fust’s continuous service (footnote F1).
• No indication of a 10b5-1 plan, tax withholding, or sale tied to the grant in this filing.

Context

• RSU grants are a common form of director compensation and do not represent immediately tradable shares until they vest and convert to common stock.
• This is an award (not a purchase or sale), so it’s a routine compensation event rather than a direct buy/sell signal.